B-cell lymphoma 2 mRNA (BCL2 mRNA) initiation codon region (BCL2 mRNA)

The B-cell lymphoma 2 (BCL2) mRNA initiation codon region is a specific sequence within the BCL2 transcript that serves as a target for antisense therapy (Gleave & Monia, 2005). BCL2 is a critical anti-apoptotic protein that prevents programmed cell death by maintaining mitochondrial membrane integrity (UniProt P10415). In many malignancies, BCL2 is overexpressed, allowing cancer cells to evade apoptosis and resist conventional chemotherapy (O'Brien et al., 2007). By targeting the translation initiation site of the BCL2 mRNA, antisense oligonucleotides like Oblimersen (G3139) can hybridize to the sequence and induce RNase H-mediated cleavage of the mRNA (Klasa et al., 2002). This reduction in mRNA levels leads to a decrease in BCL2 protein synthesis, thereby lowering the threshold for apoptosis and enhancing the efficacy of cytotoxic drugs (Rojas et al., 2004). Although clinical trials for drugs targeting this region faced challenges regarding overall survival benefits, the BCL2 mRNA remains a significant historical and theoretical target in oncology (Kim et al., 2004). The specificity of this target region is designed to prevent the translation of the BCL2 protein without affecting other members of the BCL2 family (Gleave & Monia, 2005).

Other names

bcl-2 mRNA initiation codon regionBCL2 translation initiation siteBCL2 mRNA start codon regionB-cell CLL/lymphoma 2 mRNA initiation regionG3139 target site

Antisense oligonucleotide binding to the initiation codon region of BCL2 mRNA, leading to RNase H-mediated degradation of the transcript and subsequent reduction in BCL2 protein expression (Gleave & Monia, 2005; Klasa et al., 2002).